Can a combination approach improve the efficacy of ziftomenib in AML patients with KMT2A rearrangements?

Raludotatug deruxtecan, ABBV-383 and zongertinib advance into phase 3, while other pivotal programmes are expanded.

As a key mid-stage readout approaches for the group’s neoantigen immunotherapy, Gritstone still has much to prove.

The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.

Crossover hits overall survival, pouring doubts on the group’s deal hopes.

Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.